Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481054 | 0.98 | MAPK14 (0.58) | MAPK14ADORA2ANR4A2KDM4EMEN1 | |
| SCHEMBL24212672 | 0.93 | MAPK14 (0.49) | MAPK14ADORA2ANR4A2MEN1KMT2A | |
| SCHEMBL2778903 | 0.89 | MAPK14 (0.73) | MAPK14 | |
| 2-Mercaptoethanol SCHEMBL11752092 | 0.86 | MAPK14 (0.46) | MAPK14ADORA2ANR4A2KDM4EMEN1 | |
| Propionic Acid SCHEMBL28177650 | 0.84 | ADORA2A (0.51) | MAPK14ADORA2ANR4A2KDM4EMEN1 | |
| SCHEMBL23596810 | 0.83 | ADORA2A (0.42) | MAPK14ADORA2ANR4A2KDM4EMEN1 | |
| SCHEMBL11756258 | 0.82 | MAPK14 (0.46) | MAPK14ADORA2ANR4A2KDM4EMEN1 | |
| SCHEMBL8140692 | 0.82 | CA2 (0.60) | CYP3A4 | |
| SCHEMBL11750960 | 0.82 | MAPK14 (0.43) | MAPK14ADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL11752620 | 0.82 | MAPK14 (0.49) | MAPK14ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 797 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116789624-A | Chromophore, preparation method thereof, organic electro-optic material and application thereof | 华为技术有限公司 | 2023-09-22 | — | — | CN | claimed |
| US-10065935-B2 | Derivatives of (Z)-1,2-diphenylethene | UNIWERSYTET MEDYCZNY IM. KAROLA MARCINKOWSKIEGO (PL) | 2018-09-04 | — | — | US | claimed |
| EP-2885280-A1 | THE NEW DERIVATIVES OF (Z)-1,2-DIPHENYLETHENE | Uniwersytet Medyczny Im. Karola Marcinkowskiego (PL) | 2015-06-24 | — | — | EP | claimed |
| US-20150065727-A1 | THE NEW DERIVATIVES OF (Z)-1,2-DIPHENYLETHENE | UNIWERSYTET MEDYCZNY IM. KAROLA MARCINKOWSKIEGO (PL) | 2015-03-05 | — | — | US | claimed |
| WO-2013147629-A1 | THE NEW DERIVATIVES OF (Z)-1,2-DIPHENYLETHENE | UNIWERSYTET MEDYCZNY IM. KAROLA MARCINKOWSKIEGO (PL) | 2013-10-03 | — | — | WO | claimed |
| US-20090076033-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | ROBL JEFFREY A | 2009-03-19 | — | — | US | claimed |
| EP-1121129-B1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | claimed |
| US-7390824-B1 | Method for treating diabetes employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | claimed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | claimed |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-11-18 | — | — | US | claimed |
| CN-1319012-A | Methods of treating diabetes with aP2 inhibitors and combinations thereof | BRISTOL MYERS SQUIBB CO (US) | 2001-10-24 | — | — | CN | claimed |
| EP-1121129-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-08 | — | — | EP | claimed |
| EP-1113801-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-11 | — | — | EP | claimed |
| WO-2000015230-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| WO-2000015229-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| US-5142545-A | LASER DYE | LAMBDA PHYSIK GESELLSCHAFT ZUR HERSTELLUNG VON LASERN MBH (DE) | 1992-08-25 | — | — | US | claimed |
| US-4891305-A | LASERS | RICOH CO., LTD. (JP) | 1990-01-02 | — | — | US | claimed |
| US-4102688-A | CONTAINING PYRAZOLO(3,4-B)PYRIDINE/3,6-DIONE MOIETY | FUJI PHOTO FILM CO., LTD. (JP) | 1978-07-25 | — | — | US | claimed |
| US-3970461-A | Fogged, direct-positive silver halide emulsion containing carbocyanine dye having indolenine nucleus | FUJI PHOTO FILM CO., LTD. (JA) | 1976-07-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | MAPK14 2533/4885ADORA2A 2914/4885NR4A2 357/4885 |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | MAPK14 1387/4885ADORA2A 2787/4885NR4A2 534/4885 |
| US-10065935-B2 | Derivatives of (Z)-1,2-diphenylethene | TUBB1, IPO5, TUBB3 | MAPK14 1775/4885ADORA2A 3750/4885NR4A2 3141/4885 |
| US-20150065727-A1 | THE NEW DERIVATIVES OF (Z)-1,2-DIPHENYLETHENE | TUBB1, TUBA1C, TUBB3 | MAPK14 1419/4885ADORA2A 3571/4885NR4A2 3294/4885 |
| US-20090076033-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, HMGCR | MAPK14 2320/4885ADORA2A 3475/4885NR4A2 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.